Efficacy of Isradipine in Early-Stage Parkinson Disease
Researchers assessed the effect of isradipine on clinical progression in previously untreated patients with early-stage PD.
Parkinson Disease
Abnormal Cerebral Blood Flow May Influence the Etiology of Parkinson Disease
Patients with Parkinson disease tend to have an increase in iron content with reduced perfusion in the substantia nigra.
Iron Deposition Provides Cognitive Clues in Patients With Parkinson Disease
Up to half of patients with Parkinson disease are also diagnosed with dementia, but tools to track changes in cognition are lacking.
Benefits of Bladder Training for Lower Urinary Tract Symptoms in Parkinson Disease
Bladder training and conservative advice may improve lower urinary tract symptoms in patients with Parkinson disease.
Possible Molecular Signature for Young-Onset Parkinson Disease Identified
There is a distinct genetic signature for young-onset Parkinson disease even in cells from those who have no known Parkinson disease-related mutations.
Outpatient Palliative Care Improves Outcomes in Parkinson Disease
Compared with standard care alone, outpatient palliative care is associated with benefits among patients with Parkinson disease and related disorders.
Deep Brain Stimulation Successfully Treats Refractory OCD Although Targets Vary
Responses to treatment depend on the target chosen, with 5 targets yielding positive outcomes, including the ventral anterior limb of the internal capsule, subthalamic nucleus, nucleus accumbens, ventral capsule/ventral striatum, or inferior thalamic peduncle, all involving fronto-striato-thalamocortical circuits.
Deep Brain Stimulation System Gains Expanded Approval for Parkinson Disease Management
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
Gut Inflammation Linked to the Development of Parkinson Disease
A growing body of research points to the role of the gut-brain axis in the development of Parkinson disease, with inflammatory bowel disease, leaky gut, and altered gut microbiota observed in the gut, often years before the onset of symptoms of Parkinson disease.
FDA to Review Resubmitted NDA for Apomorphine Sublingual Film
The FDA has accepted for review the resubmitted New Drug Application (NDA) for apomorphine sublingual film (APL-130277; Sunovion) for the treatment of OFF episodes in patients with Parkinson disease (PD).
Next post in Movement Disorders
